Emma Walmsley, GSK CEO (GSK Investor Day 5)
July 15, 2022 10:29 AM EDTUpdated July 18, 06:56 AM
Bioregnum
Pharma

As the con­sumer group splits away to­day, what will New GSK buy now?

What a dif­fer­ence one re­al­ly good Phase III read­out and a cou­ple of late-stage buy­outs can make.

GSK CEO Em­ma Walm­s­ley has been try­ing, hard …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times